Marc LallemantBilly AmzalPatumrat SripanSaïk UrienTim R. CresseyNicole Ngo-Giang-HuongVirat KlinbuayaemBoonsong RawangbanPrapan SabsanongThitiporn SiriwachirachaiTapnarong JarupanichPrateep KanjanavikaiPhaiboon WanasiriSuporn KoetsawangGonzague JourdainSophie Le CoeurUniversité de ParisINED Institut National d' Études DémographiquesHarvard T.H. Chan School of Public HealthHatyai HospitalBanglamung HospitalKasetsart UniversityThailand Ministry of Public HealthKhon Kaen Regional HospitalMahidol UniversityChiang Mai UniversityLASER AnalyticaParis Centre Descartes Necker CochinInstitut de recherche pour le développement (IRD) UMI 174-PHPT2020-08-252020-08-252020-07-01Journal of acquired immune deficiency syndromes (1999). Vol.84, No.3 (2020), 313-322194478842-s2.0-85086524375https://repository.li.mahidol.ac.th/handle/20.500.14594/58109INTRODUCTION: Infants born to women living with HIV initiating combination antiretroviral therapy (cART) late in pregnancy are at high risk of intrapartum infection. Mother/infant perinatal antiretroviral intensification may substantially reduce this risk. METHODS: In this single-arm Bayesian trial, pregnant women with HIV receiving standard of care antiretroviral prophylaxis in Thailand (maternal antenatal lopinavir-based cART; nonbreastfed infants 4 weeks' postnatal zidovudine) were offered "antiretroviral intensification" (labor single-dose nevirapine plus infant zidovudine-lamivudine-nevirapine for 2 weeks followed by zidovudine-lamivudine for 2 weeks) if their antenatal cART was initiated ≤8 weeks before delivery. A negative birth HIV-DNA polymerase chain reaction (PCR) followed by a confirmed positive PCR defined intrapartum transmission. Before study initiation, we modeled intrapartum transmission probabilities using data from 3738 mother/infant pairs enrolled in our previous trials in Thailand using a logistic model, with perinatal maternal/infant antiretroviral regimen and predicted viral load at delivery as main covariates. Using the characteristics of the women enrolled who received intensification, prior intrapartum transmission probabilities (credibility intervals) with/without intensification were estimated. After including the transmission data observed in the current study, the corresponding Bayesian posterior transmission probability was derived. RESULTS: No intrapartum transmission of HIV was observed among the 88 mother/infant pairs receiving intensification. The estimated intrapartum transmission probability was 2·2% (95% credibility interval 0·5-6·1) without intensification versus 0·3% (0·0-1·6) with intensification. The probability of superiority of intensification over standard of care was 94·4%. Antiretroviral intensification appeared safe. CONCLUSION: Mother/infant antiretroviral intensification was effective in preventing intrapartum transmission of HIV in pregnant women receiving ≤8 weeks antepartum cART.Mahidol UniversityMedicineArticleSCOPUS10.1097/QAI.0000000000002350